The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD) represents a selective update of the prior guideline published in 2009.

2024年4月3日 · Chronic kidney disease–mineral bone disorder (CKD-MBD) is a complex syndrome characterized by disruptions in calcium, phosphate, parathyroid hormone (PTH), vitamin D, and fibroblast growth factor-23 (FGF23) levels.

Mineral and bone disorder in chronic kidney disease (CKD) is a disorder that can affect the bones, heart, and blood vessels of a person with CKD. Mineral and bone disease occurs when kidneys damaged by CKD can’t filter blood and regulate hormones the way they should.

CKD-MBD in KTRs is an even more heterogeneous disease than in nontransplant patients. It is the consequence of many different factors, including pretransplant CKD-MBD, effects of immunosuppressive drugs, level of kidney function recovery and risk factors for osteoporosis.

Chronic kidney disease (CKD) is a worldwide health problem affecting 5–10% of the world’s population 1, 2 and the majority of these patients are at an increased risk of developing disturbances of bone and mineral metabolism.

Chronic kidney disease (CKD) is commonly associated with disorders of mineral and bone metabolism, manifested by either one or a combination of the following three components: Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and vitamin D metabolism.

Kidney Disease Outcomes Quality Initiative (KDOQI) recommends BMD measurements by dual-energy x-ray absorptiometry (DXA) only in patients in which fractures have occurred, and Kidney Disease Improving Global Outcomes (KDIGO) recommends explicitly against BMD measurements in CKD-3 to CKD-5D patients (3, 4).

2025年3月1日 · Chronic kidney disease–mineral and bone disorder (CKD-MBD) affects the skeletal and cardiovascular systems, occurs across all CKD stages, and results from the individual and combined effects of traditional and CKD-specific risk factors for skeletal and cardiovascular diseases (Figure 1).

2019年12月24日 · Despite the availability of global and regional guidelines to curtail the adverse clinical outcomes associated with chronic kidney disease-mineral and bone disorder (CKD-MBD), most CKD patients are still affected by the consequences of abnormalities of CKD-MBD. This important clinical complication o …

2020年11月15日 · The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive reduction of kidney function greatly modifies the tightly interrelated mechanisms that control these parameters.